Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation - Wikidata - awgldk - TriplyDB

Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation

Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation

http://www.wikidata.org/entity/Q58048140

about

Complement cascade and kidney transplantation: The rediscovery of an ancient enemy Antiphospholipid syndrome in renal transplantation.36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature.Difficult clinical situations in the antiphospholipid syndrome.The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.Complement involvement in kidney diseases: From physiopathology to therapeutical targeting Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.The antiphospholipid syndrome: still an enigma Living donor renal transplantation in patients with antiphospholipid syndrome: A case report.Antiphospholipid syndrome: an update.Antiphospholipid syndrome, antiphospholipid antibodies and solid organ transplantation.Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.Treatment of catastrophic antiphospholipid syndrome Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?Current status and future prospects for the treatment of antiphospholipid syndrome.Kidney disease in primary anti-phospholipid antibody syndrome.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Stratification of responders towards eculizumab using a structural epitope mapping strategy.Pharmacologic Complement Inhibition in Clinical Transplantation.Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.The role of complement inhibition in kidney transplantation.Diagnosis and management of the antiphospholipid syndrome.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.Transplant glomerulopathy.Antibody-mediated rejection: New approaches in prevention and management.Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.

P2860

Q26829790-895B9CA8-FCC0-4DAD-9FAF-AC2137139755 Q33413394-4FEEECB2-B847-4CCA-8758-AA85CDC4F3C6 Q33418663-0404541D-8B88-45AF-A336-70A48C9537B0 Q33421814-9FC99B65-7086-4CD3-A9DA-1A7CFDCF625A Q33431097-3F510185-2578-4337-9CA2-33F2B61726D2 Q33439133-745B232E-1142-4657-8AF4-C5A7E2BF91A3 Q35567841-EAC74E10-1B43-416C-90B2-11B61C2F832A Q35621012-849F3DCE-8AB2-41A9-A47D-1D79BCEBD639 Q36928593-4887CD0A-F13B-4EC3-B1FE-20048823000B Q37433100-AAF34A96-FC6A-4129-B6F6-98B6DEB97F1E Q38410376-6F13D5E0-8E66-4C79-8158-89189D141D3E Q38544987-2A1E1D40-C5F2-41AE-BDB2-116C0E9F98E9 Q38657043-391567E8-157B-4D53-86F0-35FD4030A646 Q38755260-851B56DC-B284-4C33-9371-01625844DCE6 Q38794847-CBB8A5A0-19D0-4807-8FE9-959219F41C54 Q38818425-62FD1402-7B76-4786-9E32-F1518723FBD2 Q38934375-C580B35F-593A-403F-A312-71DD5CD4D840 Q39218839-2DF12814-02A4-4664-8A69-2A527124D3B0 Q39450682-B284B9A0-A068-452F-AE30-E5E25E6BA7ED Q42086661-507EF0B6-89D2-4438-9867-63CE111D5C92 Q42364725-28B45224-211A-42D6-B9AD-CBB5F9D3C2CA Q47104714-EA5A15F5-4157-4551-B493-5EC981A6DFE9 Q47640137-BE1F02AB-5B1B-450D-A836-FE50B1E12C2A Q47720351-C6D233DB-C65B-4EDB-93DD-081A2E8FA783 Q47982275-6675ED2F-336C-448D-BD67-30670A8F4A6B Q47998109-A1810AFD-9428-45AC-89FA-EE3C81442BA0 Q50063069-6E06B645-1FBC-4869-AE2E-7980A1B27074 Q52401610-91E88214-F4E9-4721-A9DB-8526CC6C2DF3 Q55177568-DCA1E524-D52E-431D-AC7D-CCFBEFB932EC

P2860

Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation

http://www.wikidata.org/entity/Q58048140

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Eculizumab Prevents Recurrent ...... ccessful Renal Transplantation

@en

Eculizumab Prevents Recurrent ...... ccessful Renal Transplantation

@nl

type

label

Eculizumab Prevents Recurrent ...... ccessful Renal Transplantation

@en

Eculizumab Prevents Recurrent ...... ccessful Renal Transplantation

@nl

prefLabel

Eculizumab Prevents Recurrent ...... ccessful Renal Transplantation

@en

Eculizumab Prevents Recurrent ...... ccessful Renal Transplantation

@nl

P1433

Q58048140-9CD9BB0C-6631-4D13-BF66-89FAD93833FD

P1476

Q58048140-ECDCCAA4-4ADE-4AE7-8DD5-1F45D2FDE8F8

P2093

Q58048140-116D6C7D-B02B-4EA5-856F-74760B556D77

Q58048140-31382EA2-DBBF-478A-9C28-68F88F59A1FF

Q58048140-400BFD63-B212-4B6A-941B-6D914499EAAB

Q58048140-563DA071-4A4E-4327-9D96-A373F6FFFC95

Q58048140-6B368D5F-83E2-4DDE-8976-CBBF6BC298AA

Q58048140-7D3201DA-4648-406E-97A7-129324D591B3

Q58048140-9E80E977-4751-4352-9643-5C6E672D3B83

Q58048140-9EFA92EF-ED9E-4316-BF31-5044DF6876BB

Q58048140-BD737B5A-7C9D-45E5-9200-D9343DFA2E5C

Q58048140-C20DA81D-1FE3-4EFF-BAF5-0860A09135E7

P2860

Q58048140-0CECFF8E-03DE-4624-95B4-4E3856FC1862

Q58048140-0DA9314A-058C-41B3-A579-C660A3A52EF5

Q58048140-17BC8E49-EDEE-4D83-83FA-35D08B2E3E39

Q58048140-279F5D7B-7463-4593-9135-EF484F90D844

Q58048140-2B3CD76F-2CB7-40DD-BCC2-2FD5E66F92A4

Q58048140-32E94EF2-01DC-458C-8522-07E966479C41

Q58048140-3DDDF68F-10A3-4B6A-909B-3D0900926941

Q58048140-474E9B97-C8CF-4553-B2F2-CA4EFA5AE19F

Q58048140-4FCF0521-E7A5-474F-98F1-CBF469CB2776

Q58048140-527565F7-AE25-4ACE-AF7F-0EFC0D6D6331

P304

Q58048140-A14289D3-1AF6-4846-8BD3-015BEF5BAB6F

P31

Q58048140-F45F0BA9-D432-490D-A246-9C29389F0994

P356

Q58048140-82B5A847-695C-4482-970E-3FEA8B98CA39

P407

Q58048140-49BB7B02-81D8-417A-BCEA-4D1D87862D6A

P433

Q58048140-8242165C-EB3C-435B-A38A-F8607633FCDD

P478

Q58048140-F4FAFC38-B888-47FD-95CC-537CB4F72D9F

P50

Q58048140-50CE1763-0323-4699-99BE-CC3E6E3C730F

Q58048140-F016ADC1-BB47-4B05-A5D7-F8F9CC57B9AB

P577

Q58048140-80FDE778-098C-467F-8AD8-191F5BA27B09

P698

Q58048140-F03D2916-C919-44EB-8656-388D2250B963

P921

Q58048140-1E5A0DE1-3AC7-4B0A-B1F3-C239D2B87965

P356

P1433

American Journal of Transplantation

P1476

Eculizumab prevents recurrent ...... ccessful renal transplantation

@en

P2093

A A Zachary

http://www.w3.org/2001/XMLSchema#string

A L Singer

http://www.w3.org/2001/XMLSchema#string

B J Orandi

http://www.w3.org/2001/XMLSchema#string

C M Magro

http://www.w3.org/2001/XMLSchema#string

D L Segev

http://www.w3.org/2001/XMLSchema#string

M B Streiff

http://www.w3.org/2001/XMLSchema#string

N Carter-Monroe

http://www.w3.org/2001/XMLSchema#string

N M Desai

http://www.w3.org/2001/XMLSchema#string

R A Montgomery

http://www.w3.org/2001/XMLSchema#string

S M Nazarian

http://www.w3.org/2001/XMLSchema#string

P2860

Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Eculizumab and renal transplantation in a patient with CAPS

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome

Possible role of hypercoagulability in calciphylaxis: review of the literature.

The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence.

Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.

P304

459-465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJT.12540

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Bonnie E. Lonze

P577

2014-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24400968

http://www.w3.org/2001/XMLSchema#string

P921